Go online to PeerView.com/EAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and recent approval of a novel adoptive immunotherapy—chimeric antigen receptor (CAR) T cell therapy—offers hope for many patients underserved by standard options. Although initial regulatory approvals have occurred in diseases such as ALL and DLBCL, new evidence is suggesting that CAR T cells will play a role in the care of patients with clear medical needs in settings such as CLL and MCL. In this CME-accredited PeerView MasterClass on-demand activity, experts in hematology and oncology dive into the science behind CAR T cells for patients with hematologic malignancies and discuss strategies for appropriately integrating this innovative therapeutic approach into current management protocols. In doing so, the panel discusses evidence for approved CAR T options, offers insights on its future applications in several different hematologic cancers, and assesses its potential as an alternative to hematopoietic stem cell transplantation (HCT). Throughout, the experts share practical information on toxicity mitigation strategies for adverse events and real-world patient management with CAR T cells, as well as several illustrative cases that highlight patient outcomes with cellular therapy. Upon completion of this activity, participants should be better able to: Summarize the latest evidence on the efficacy and safety of adoptive immunotherapy with CAR T cells in various B-cell malignancies, Assess the clinical role and benefits of CAR T cell therapy in eligible patients with leukemia and lymphoma, Safely and effectively apply approved and emerging CAR T cell treatment strategies, including appropriate referrals to specialized centers and enrollment in clinical trials, for the management of patients with leukemia